MedTrace Logo

Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.

NCT03018236 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-01-24

No results posted yet for this study

Summary

This study evaluates the use of N-acetylcysteine in the treatment of alcohol and cocaine use disorders. Alcohol users will be split in two groups, one will receive the active N-acetylcysteine and the other placebo. The same division will occur with cocaine users. The effects of N-acetylcysteine in adherence, abstinence, psychiatric symptoms and stress biomarkers will be evaluated.

Conditions

  • Cocaine Addiction
  • Alcohol Addiction

Interventions

DRUG

Alcohol N-acetylcysteine

1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder

DRUG

Alcohol Placebo

Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder

DRUG

Cocaine N-acetylcysteine

1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder

DRUG

Cocaine Placebo

Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder

Sponsors & Collaborators

  • Secretaria Nacional de Políticas sobre Drogas (SENAD)

    collaborator UNKNOWN

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Lisia von Diemen, PhD · Federal University of Rio Grande do Sul (UFRGS)

  • Flavio Pechansky, PhD · Federal University of Rio Grande do Sul (UFRGS)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-07-31
Completion
2018-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03018236 on ClinicalTrials.gov